Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Memorial Sloan Kettering Cancer Center (MSK)

Status: Enrolling

Conditions: Lymphoma, B-Cell; Large B-cell Lymphoma; DLBCL - Diffuse Large B Cell Lymphoma; Lymphoma; Mediastinal B-Cell Diffuse Large Cell Lymphoma; Large-cell Lymphoma

Treatments: Behavioral: Participants Appointment; Behavioral: Hematolo-GIST Training

Study type: Interventional

Funder types: Other

Identifiers

NCT05940272

23-164

Details and patient eligibility

About

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Enrollment: 48 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Providers

• Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)

Patients

• Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)

• Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma

• Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)

• Self-identify as Black and/or White

• Per medical record, 18 years of age or older

• Per self-report, fluent in English**

  • Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:

    1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
    2. What is your preferred language for healthcare? (must respond English)

Exclusion criteria

Providers

• Per self-report, planning to leave the cancer center in the next 12 months

Patients

• Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
• Per research staff judgment and/or self-report, too ill or weak to complete study procedures
• Per medical record or self-report, receiving hospice care at the time of enrollment

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

48 participants in 2 patient groups

Hematologists

Experimental group

Description:

Hematologists will be recruited from the lymphoma clinics at MSK

Treatment:

Behavioral: Hematolo-GIST Training

Participants Patients

Experimental group

Description:

Participant patients are being treated by a hematologic oncologist participating in this study

Treatment:

Behavioral: Participants Appointment